ACTRN12621001397808招募中未知
The Haemophilia Osteoporosis Registry (THOR): Identifying Mechanisms of Bone Loss in Haemophilia
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 176
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Male
入选标准
- •Eligibility for inclusion as a participant in this study will require a potential participant to satisfy all of the following eligibility criteria:
- •- Aged 18 years or older
- •- Body weight less than 160 kg (maximum rating of imaging machines).
- •- At least one side of the body must be free from any metal, or other material in limbs or surrounding locations, that could interfere with imaging.
- •- Fluent in written and spoken English, has capacity to provide informed consent and can communicate effectively with researchers. A legally acceptable representative and/or impartial witness fluent in written and spoken English and the participant’s first/fluent language acting as translator will also be acceptable, providing they are able to attend all scheduled sessions with the participant.
- •Patients with haemophilia recruited for the study should also satisfy the additional criterion below:
- •- Previously diagnosed with moderate to severe haemophilia A
- •Participants in the control group should also satisfy the additional criteria below:
- •- Be in good health without any major medical co-morbidities (diabetes, chronic kidney disease and recent cardiovascular events – stroke, myocardial infarction or heart attack)
- •- No other medical condition that in the opinion of the investigators may deem inclusion unsafe or inappropriate (e.g., recent exposure to nuclear medicine; conditions that may reduce ability to remain supine during DXA (e.g., vertigo); conditions that may reduce ability to remain still during scans (e.g. Parkinson’s disease, motor-neuron disease).
- •- Not be on medications that targets bone health e.g., Alendronate (Fosamax), Risedronate (Actonel), Ibandronate (Boniva), Zoledronate (Aclasta), Denosumab (Prolia), Teriparatide (Forteo) and Romosozumab (Evenity).
排除标准
- •For all participants:
- •- Have other medical condition that in the opinion of the investigators may deem inclusion unsafe or inappropriate (e.g., recent exposure to nuclear medicine; conditions that may reduce ability to remain supine during DXA (e.g., vertigo); conditions that may reduce ability to remain still during scans (e.g. Parkinson’s disease, motor-neuron disease).
- •Control participants:
- •- On medications that targets bone health e.g., Alendronate (Fosamax), Risedronate (Actonel), Ibandronate (Boniva), Zoledronate (Aclasta), Denosumab (Prolia), Teriparatide (Forteo) and Romosozumab (Evenity).
研究者
相似试验
招募中
不适用
Haemoglobinopathy RegistrySickle cell diseaseThalassaemiaBlood - Other blood disordersACTRN12617000051347Monash University1,000
已完成
不适用
Haemophilia and Bone Loss - PHILEOS StudyHemophiliaNCT04384341Centre Hospitalier Universitaire de Saint Etienne448
招募中
不适用
Inherited Bone Marrow Failure Syndrome RegistryInherited bone marrow failure syndromeJPRN-UMIN000042088Hirosaki University Graduate School of Medicine9,999
已完成
不适用
Construction of registry of patients with ossification of posterior longitudinal ligament: A prospective multi-center studyOPJPRN-UMIN000035194Japanese organization of the Study for Ossification of Spain Ligament680
招募中
不适用
Hip Fracture Registry CohortDiseases of the musculo-skeletal system and connective tissueKCT0002042Chung-Ang Univerisity Hospital5,400